Studies Actively Enrolling
- 20863: Development of a Patient-Reported Outcome Measure for Cutaneous Chronic GVHD
- 20804: Axatilimab for Sclerotic Chronic Graft-versus-Host Disease
- 20163: Randomized phase II study of belumosudil vs. placebo for preemptive treatment of chronic graft-versus-host disease
- 10360: Predicting the Quality of Response to Specific Treatments (PQRST)
Studies Open for Follow-Up and Data Analysis Only
- 10582: Early Measurement of ST2 as a Prognostic Biomarker for Future Occurrence of Acute GVHD II-IV in a Prospective Multisite Study
- 10421: Randomized, placebo-controlled, phase II trial examining ustekinumab for prevention of graft vs. host disease after allogeneic hematopoietic cell transplantation
- 10391: Long-Term Oral Health Outcomes in the Chronic GVHD Consortium
- 10134: Close Assessment and Testing for Chronic GVHD (The CATCH Study)
- 8801: Acalabrutinib for Chronic Graft-versus-Host Disease
- 8771: A Single-Arm, Open-Label, Phase I/II Study of Glasdegib for Sclerotic Chronic Graft-vs-Host Disease
- 8735: A Single Arm, Open Label, Phase II Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease after a Failure of Systemic Glucocorticoids
- 8708: Multi-Site Randomized Trial of Inpatient Palliative Care for Patients with Hematologic Malignancies Undergoing Hematopoietic Stem Cell Transplantation
- 2732: Chronic GVHD Response Measures Validation: Control Cohort
- 2710: Chronic GVHD Response Measures Validation
- 2342: Longitudinal Study of Immune Mediated Disorders after Allogeneic Hematopoietic Cell Transplantation
- 2207: Late Effects of Stem Cell Transplantation
- 2192: Improving Outcomes Assessment in Chronic Graft versus Host Disease
Open Industry-Sponsored Studies
- 20375: A Randomized, Double-Blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of Belumosudil in Combination with Corticosteroids versus Placebo in Combination with Corticosteroids in Participants at least 12 Years of Age with Newly Diagnosed Chronic Graft versus Host Disease
- 10866: Extended Treatment and Follow-up of Subjects Treated with Belumosudil in Study KD025-208 or Study KD025-213
- 10608: AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients with Recurrent or Refractory Active Chronic Graft Versus Host Disease who have Received at least 2 Lines of Systemic Therapy
Closed Clinical Trials
- 9962: Randomized Feasibility Study of Discontinuation versus Continuation of Immunosuppressive Therapy (IST) in Patients with Chronic Graft Versus Host Disease (GVHD)
- 9728: Test-Retest Reliability of the Lee Chronic GVHD Symptom Scale
- 9514: Ofatumumab in Combination with Glucocorticoids for Primary Therapy of Chronic Graft versus Host Disease
- 9421: Patient Feedback about the Chronic Graft versus Host Disease Symptom Scale
- 9292: Ixazomib for Treatment of Chronic Graft versus Host Disease
- 9228: Carfilzomib for Treatment of Chronic Graft versus Host Disease
- 2676: Survey of Transplant Clinicians Regarding Diagnosis, Grading, and Management of Chronic GVHD
- 2663: Provider Survey on Frequently Asked Questions About the National Institutes of Health (NIH) Consensus for Chronic Graft-versus-Host Disease (GVHD)
- 2659: Feasibility of Implementing Pre-Transplant Evaluation by the Supportive Care Team for Patients Undergoing Hematopoietic Cell Transplantation for Hematological Malignancies
- 2617: A Phase II Study of Bandage Lenses for Ocular Graft-versus-host Disease after Allogeneic Hematopoietic Cell Transplantation
- 2563: Costs of HCT
- 2443 (BMT CTN 0902): A Phase III Randomized, Multicenter Trial Testing Whether Exercise or Stress Management Improves Functional Status and Symptoms of Autologous and Allogeneic Recipients
- 2436: Biomarkers in Chronic Graft versus Host Disease
- 2367: Targeted Therapy of Bronchiolitis Obliterans Syndrome (FAM for BOS)
- 2343: A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis after Allogeneic Hematopoietic Cell Transplantation
- 2341: Personality and Patient Self-Reported Measures
- 2321: A Randomized Placebo-Controlled, Double-Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation
- 2317: Multi-Institutional Phase II Study of Montelukast for the Treatment of Bronchiolitis Obliterans Following Allogeneic Stem Cell Transplantation in Children and Adults
- 2250: A Randomized Multicenter Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies
- 2160: Advance Care Planning and Symptom Management in Stem Cell Transplantation
- 2109: Physician-patient Communication in Hematologic Malignancies
Closed Industry-Sponsored Studies
- 10068: A Phase 1, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of SNDX-6352 in Subjects with Active Chronic Graft Versus Host Disease who have Received at least 2 Lines of Prior Therapy, Including Ibrutinib
- 9926: A Phase 1b/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 592 in Adult Subjects With Steroid Refractory Chronic Graft versus Host Disease
- 9643: A Phase 2a, Dose-Escalation, Open-Label Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects with Chronic Graft Versus Host Disease
- 8699: A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Chronic Graft Versus Host Diseasse (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study)